---
title: "Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Contraindications/Warnings/Precautions/Adverse effects"
description: "Formulary evidence on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks: Contraindications/Warnings/Precautions/Adverse effects. Covers Warnings and precautions. 16 evidence topics quoted from 13 sources."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description/contraindications-warnings-precautions-adverse-effects"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Contraindications/Warnings/Precautions/Adverse effects

<a id="heading-2.1.2.7"></a>

## 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

### 2.1.2.7.1 Warnings and Precautions

<a id="topic-2.1.2.7.1-1"></a>

#### FDA-approved prescribing information for deucrictibant

Not applicable.

<a id="topic-2.1.2.7.1-2"></a>

#### Participants exposed across the clinical studies, data cutoff June 10, 2026

> “As of June 10, 2026, 743 unique participants are estimated to have been exposed to deucrictibant across 25 Pharvaris-sponsored clinical studies (based on number of participants treated with deucrictibant in open-label or completed studies and on randomization ratios for blinded trials ongoing at the time of data cutoff):”
> “339 were healthy participants, 16 had hepatic impairment, 24 had renal impairment, and approximately 312 were participants with HAE.”

Source: [Lesage et al. (2026a)](https://ir.pharvaris.com/static-files/832a8830-6fd1-41ac-b767-e1b348388853)

<a id="topic-2.1.2.7.1-3"></a>

#### Integrated cardiovascular adverse events across phase 1, phase 2, and phase 3 studies

> “There were no system organ class (SOC) cardiac disorder or SOC vascular disorder treatment-related treatment-emergent adverse events (TEAEs) across Phase 1 single-dose studies, RAPIDe-1, CHAPTER-1 RCT, RAPIDe-2 Part A, or RAPIDe-3.”
> “Of the 232 healthy participants receiving deucrictibant in Phase 1 multiple-dose studies, there were no SOC cardiac disorder treatment-related TEAEs, and 1 (0.4%) participant experienced an SOC vascular disorder TEAE of orthostatic hypotension considered related to treatment.”
> “Of 110 participants in the ongoing RAPIDe-2 Part B, there were no SOC vascular disorder treatment-related TEAEs, and 1 (0.9%) experienced an SOC cardiac disorder TEAE of tachycardia considered related to treatment.”
> “Overall, in these studies, no evidence of increased risk of CV events was observed.”

Source: [Lesage et al. (2026a)](https://ir.pharvaris.com/static-files/832a8830-6fd1-41ac-b767-e1b348388853)

<a id="topic-2.1.2.7.1-4"></a>

#### Concentration-QTc analysis of pooled phase 1 studies

> “A meta-analysis of pooled data from two single ascending dose (SAD) and one multiple ascending dose (MAD) Phase 1 studies.”
> “The highest mean maximum plasma concentration (Cmax) in the meta-analysis was 693 ng/mL, substantially higher than the concentration estimated to provide 85% maximal response (EC85: 13.8 ng/mL).”
> “The C-QTcF model estimated a slope of −0.00453 ms/(ng/mL) between deucrictibant plasma concentration and QTcF, which was statistically and clinically non-significant (P=0.1858 based on two-sided t-test).”
> “In the highest estimated clinical exposure scenario, the expected mean Cmax was approximately 840.6 ng/mL. The C-QTcF model dataset contained individual plasma concentrations up to 1550 ng/mL, nearly twice this value.”
> “The ΔΔQTcF in this scenario resulted in a slight negative value of −2.55 ms (upper 90% CI: +2.29 ms), below the 10 ms threshold for QTc prolongation set by regulatory agencies for a clinically meaningful change.”

Source: [Lesage et al. (2026a)](https://ir.pharvaris.com/static-files/832a8830-6fd1-41ac-b767-e1b348388853)

<a id="topic-2.1.2.7.1-5"></a>

#### Nonclinical cardiovascular safety and hERG channel assay

> “Deucrictibant had no evident effects on cardiac electrophysiology, hemodynamic parameters, cardiac morphology, and histopathology evaluation in acute and chronic nonclinical safety studies in non-human primates.”
> “A manual patch-clamp assay at physiologic temperature confirmed the absence of relevant inhibition of the hERG-mediated current at deucrictibant concentrations 162-fold above the highest estimated clinical exposure.”

Source: [Lesage et al. (2026a)](https://ir.pharvaris.com/static-files/832a8830-6fd1-41ac-b767-e1b348388853)

<a id="topic-2.1.2.7.1-6"></a>

#### Thorough QT study waivers accepted by the FDA

> “Following review of preclinical and clinical data, the U.S. Food and Drug Administration (FDA) has accepted Pharvaris’ TQT study waiver requests. These waivers apply to the prophylactic program (IND153097) for deucrictibant extended-release formulation and the on-demand program (IND155872) for deucrictibant immediate-release formulation.”

Source: [Pharvaris Form 6-K, first quarter 2025 results (2025)](https://www.sec.gov/Archives/edgar/data/1830487/000095017025070308/phvs-ex99_1.htm)

<a id="topic-2.1.2.7.1-7"></a>

#### Nonclinical toxicology, genotoxicity, and phototoxicity

> “The conducted nonclinical package for deucrictibant includes secondary pharmacodynamics, safety pharmacology, genotoxicity, reproductive and developmental studies and general toxicity studies up to six months in rats and up to nine months in non-human primates. Deucrictibant did not demonstrate any in vitro or in vivo genotoxicity nor in vitro phototoxic potential. No findings considered relevant to humans were observed in GLP (Good Laboratory Practices)-compliant general toxicity studies in rats up to 3-months duration and in cynomolgus monkeys up to 9-months duration at doses up to the maximum tolerated dose in each species.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-2.1.2.7.1-8"></a>

#### FDA clinical hold based on repeat-dose rat toxicology findings, August 2022

> “the U.S. Food and Drug Administration (FDA) verbally informed Pharvaris that, based on its review of nonclinical data, the agency is placing a clinical hold on the clinical trials of PHA121 in the U.S. under two Pharvaris Investigational New Drug (IND) applications for the treatment of HAE.”

Source: [Pharvaris clinical hold press release (2022)](https://www.sec.gov/Archives/edgar/data/1830487/000156459022029851/phvs-ex991_6.htm)

> “Findings were observed in the repeat-dose rat data package that were considered not to be related to bradykinin B2 receptor antagonism. Based on review of these nonclinical findings, in 2022, the FDA put a clinical hold on trials of deucrictibant in the U.S.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

> “The agency requested that Pharvaris conduct an additional long-term rodent toxicology study and update the Investigator’s Brochure”

Source: [Pharvaris corporate presentation, January 2024 (2024)](https://www.sec.gov/Archives/edgar/data/1830487/000095017024002680/phvs-ex99_2.htm)

> “FDA has subsequently agreed to partially lift the clinical hold on RAPIDe-1 trial and allow 2 remaining U.S. participants in RAPIDe-1 to complete treatment of a final HAE attack per protocol.”

Source: [Maurer et al. (2023b)](https://ir.pharvaris.com/static-files/39663775-647d-44c4-8870-da48e883078f)

<a id="topic-2.1.2.7.1-9"></a>

#### Clinical hold lifts: on-demand IND in June 2023 and prophylaxis IND in January 2024

> “Pharvaris aligned with the FDA to conduct and complete a 26-week rodent toxicology study to address the clinical holds. Following review of data from a preplanned interim analysis of the study, the FDA lifted the clinical hold on the IND application for deucrictibant for the on-demand treatment of HAE in June 2023. In January 2024, the FDA lifted the clinical hold on the IND application for deucrictibant for the prophylactic treatment of HAE attacks following review of the full data set from the completed 26-week rodent toxicology study.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-2.1.2.7.1-10"></a>

#### Strong CYP3A4 inhibitors and inducers excluded from the phase 3 on-demand trial

> “Use of concomitant medications with systemic absorption that are strong inhibitors of CYP3A4 or strong inducers of CYP3A4 within the last 30 days, or within 5 half-lives (whichever is longer) of the time of randomization.”

Source: [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

<a id="topic-2.1.2.7.1-11"></a>

#### Immediate-release capsule in the phase 3 trial (RAPIDe-3): adverse events in the safety analysis set

> “Across the study, no treatment-related adverse events were assessed as severe or serious, and no adverse events led to treatment discontinuation.”
> “Six events in five participants in the deucrictibant group were reported as related to treatment as deemed by the investigators, all of which were observed once and resolved within 24 h spontaneously or with standard management (table 3).”
> “During the entire study, no treatment-emergent adverse events led to treatment discontinuation, or were associated with changes in clinical laboratory, vital signs, and electrocardiogram parameters.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.7.1-12"></a>

#### Immediate-release capsule in the phase 2 trial (RAPIDe-1): severity and seriousness of adverse events

> “No severe (grade 3), life-threatening (grade 4), or fatal (grade 5) treatment-emergent adverse events were reported. Additionally, no treatment-emergent adverse events were reported that were serious, led to discontinuation of treatment or from the study, or were associated with changes in laboratory or ECG parameters or vital signs (table 3).”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-2.1.2.7.1-13"></a>

#### Phase 1 tolerability of single and multiple doses in healthy volunteers

> “Adverse events (AEs) were reported by 25% of the subjects in the combined group of all subjects treated with PHA-022121, identical to the 25% incidence with placebo. There was no dose related increase in the incidence of AEs.”
> “All AEs were mild or moderate and subsided rapidly and completely.”

Source: [Crabbé et al. (2021)](https://ir.pharvaris.com/static-files/a5937e81-635a-4808-b099-3a049c87c51b)

> “PHA-022121 was well tolerated up to the highest dose of 50 mg BID. All reported treatment-emergent adverse events (TEAEs) were mild in intensity and resolved completely.”

Source: [Groen et al. (2021)](https://ir.pharvaris.com/static-files/f7f8b87d-c488-4611-b3a6-a2275aa94143)

<a id="topic-2.1.2.7.1-14"></a>

#### Prophylaxis trial of the extended-release tablet (CHAPTER-3): safety and cardiovascular outcomes over 24 weeks

> “In CHAPTER-3, 85 participants received deucrictibant (n=55) or placebo (n=30) with a median (IQR) treatment duration of 24.0 (23.7–24.0) weeks.”
> “Deucrictibant was generally well tolerated, with no treatment-related serious TEAEs and no deaths.”
> “Treatment-related TEAEs were experienced by 11 (20%) participants receiving deucrictibant and 3 (10%) receiving placebo, and 1 participant in each group discontinued study treatment due to an adverse event.”
> “There were no SOC cardiac disorder or vascular disorder TEAEs that were deemed related to deucrictibant.”
> “There were no treatment-related clinically significant abnormalities in heart rate, systolic and diastolic blood pressure, or ECG findings.”

Source: [Lesage et al. (2026a)](https://ir.pharvaris.com/static-files/832a8830-6fd1-41ac-b767-e1b348388853)

<a id="topic-2.1.2.7.1-15"></a>

#### Prophylaxis trial with twice-daily immediate-release capsules (CHAPTER-1), randomized part: treatment-related adverse events

> “Treatment-related treatment-emergent adverse events were experienced by two (18%) patients receiving deucrictibant 20 mg, one (8%) patient receiving deucrictibant 40 mg, and one (9%) patient receiving the placebo; all were mild in severity (grade 1) and did not require dosing modification of the study drug. There were no serious adverse events or deaths in any treatment group.”

Source: [Aygören-Pürsün et al. (2026a)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2826%2900004-9/fulltext)

<a id="topic-2.1.2.7.1-16"></a>

#### Prophylaxis trial (CHAPTER-1) open-label extension: long-term cardiovascular outcomes

> “In the CHAPTER-1 OLE, participants received deucrictibant for a mean (standard deviation) duration of 22.2 (8.1) months, with a maximum exposure across the entire CHAPTER-1 study of 33.8 months.”
> “Of 30 participants receiving deucrictibant in the CHAPTER-1 OLE, no treatment-related SOC cardiac disorder or SOC vascular disorder TEAEs were reported.”
> “There were no clinically significant abnormalities in laboratory parameters or ECG findings.”

Source: [Lesage et al. (2026a)](https://ir.pharvaris.com/static-files/832a8830-6fd1-41ac-b767-e1b348388853)

<a id="topic-2.1.2.7.1-17"></a>

#### Combined use of the immediate-release capsule and extended-release tablet: estimated exposure and nonclinical safety margins

> “The combined use of deucrictibant extended-release (XR) tablet 40 mg and immediate-release (IR) capsule(s) 20 mg in the event of a bradykinin-mediated angioedema attack occurring during prophylactic treatment with XR tablet is supported by adequate safety margins, subject to approval of each formulation by regulatory authorities.”
> “The anticipated human Cmax (287 ng/mL) resulted in a margin of 8.8- to 19-fold the nonclinical Cmax at the NOAEL in different species (Table 2, Figure 2A).”
> “The margin for the estimated human Cmax of 342 ng/mL was between 7.4- and 16-fold the nonclinical Cmax at the NOAEL in different species (Table 2, Figure 2A).”
> “In both combined scenarios, the estimated systemic exposure remained below the highest exposure explored in humans following clinical administration of deucrictibant as an oral solution at 50 mg BID for 10 days (Table 4, Figure 2A and 2B), a dose that was not associated with adverse reactions.”

Source: [Lesage et al. (2026b)](https://ir.pharvaris.com/static-files/67d704cc-422d-47b0-b130-9a6556fce46a)

## Related pages
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references.md)
